NCT05486481 - Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) | Biotech Hunter

Timeline

Start Date

January 8, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

AL AmyloidosisLight Chain (AL) AmyloidosisSystemic Light Chain Disease

Interventions

DRUG

Venetoclax

Given orally (PO)

DRUG

Dexamethasone

Given PO

DRUG

Daratumumab

Given Subcutaneously (SC)

DEVICE

Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence in situ hybridization (FISH) assay

Lab test